CSPC Wins China NMPA Approval for World's First Fast-Dissolving Albumin-Bound Paclitaxel in Metastatic Breast Cancer
Key Insights
CSPC Pharmaceutical Group (search) secured NMPA approval for its novel paclitaxel injection (albumin-bound) (II), claimed as the first quick-dissolving albumin-bound paclitaxel nano-formulation globally.
In a pivotal Phase III trial, the new formulation demonstrated a 27% reduction in disease progression or death risk and a 33% reduction in mortality risk versus existing nab-paclitaxel.
The product showed an 82% shorter reconstitution time and a 62% lower risk of rash, offering practical advantages for infusion centers and improved patient quality of life.
CSPC Pharmaceutical Group (search) has secured marketing approval from China's National Medical Products Administration (NMPA) for its Paclitaxel for Injection (Albumin-Bound) (II) (search), a 100 mg quick-dissolving, albumin-bound paclitaxel nano-formulation that the company claims is the first of its kind globally. Developed in-house and protected by patents in major markets, the drug is indicated for patients with metastatic breast cancer (search) whose disease has progressed after combination chemotherapy or who relapse within six months of adjuvant treatment.
The approval marks a significant milestone for CSPC's oncology portfolio and positions the company to compete directly in a segment currently dominated by existing nab-paclitaxel brands.
Pivotal Phase III Data Demonstrates Superior Efficacy
In a pivotal multicenter, randomized, double-blind Phase III trial, the new formulation showed superior efficacy compared with the existing albumin-bound paclitaxel. The trial results revealed a 27% reduction in the risk of disease progression or death and a 33% reduction in the risk of death, alongside higher objective response rates.
Beyond efficacy, the product demonstrated a notably improved safety profile, including a 62% lower risk of rash. These clinical advantages are expected to enhance treatment adherence and improve patients' quality of life.
Practical Advantages for Clinical Settings
A key differentiator of CSPC's formulation is its reconstitution profile. The product achieved an 82% shorter reconstitution time compared with conventional nab-paclitaxel products, which typically require a longer dissolution period before infusion. According to CSPC, this improved dissolution profile is intended to reduce bottlenecks in busy oncology infusion centers — a practical advantage that could accelerate adoption in large Chinese hospitals.
The company emphasized that the formulation maintains clinical equivalence on key measures such as efficacy and safety compared with marketed nab-paclitaxel while cutting preparation time and simplifying handling for hospital pharmacists and infusion nurses.
Broader Indications and Market Positioning
While the initial approval covers metastatic breast cancer (search), the NMPA authorization also encompasses indications including non-small cell lung cancer (search) and pancreatic cancer (search), aligning with the core use cases of existing nab-paclitaxel therapies in China's clinical practice guidelines.
CSPC is positioning the drug as a domestically developed alternative that can potentially lower treatment costs compared with imported brands, an argument that aligns with Beijing's broader push to encourage high-quality local generics and innovative formulations in oncology. The company plans to leverage its established hospital sales network to accelerate uptake, particularly in tier-2 and tier-3 cities where the availability of imported nab-paclitaxel can be inconsistent.
Strategic Fit Within CSPC's Pipeline
The launch fits into CSPC's broader pipeline narrative, which also includes innovative biologics such as a HER2 bispecific antibody regimen that delivered positive Phase III data at the 2026 ASCO meeting and a once-monthly semaglutide formulation for obesity now cleared by the US Food and Drug Administration to begin clinical trials.
For oncologists, faster preparation may be less headline-grabbing than a new mechanism of action, but in everyday practice it can translate into more predictable scheduling and shorter chair times. The product reinforces CSPC's status as a key domestic player in oncology and could support pricing and formulary negotiations by giving hospitals and provincial procurement bodies an additional option beyond multinational brands.